Official Journal of the European Union

C 429 I

English edition

Information and Notices

Volume 65

11 November 2022

Contents

EN

IV

(Notices)

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

EUROPEAN COMMISSION

Summary of European Union decisions on marketing authorisations in respect of medicinal products of 10 November 2022

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council [1] or Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council [2])

(2022/C 429 I/01)

— **Issuing of a marketing authorisation** (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): **Accepted**

Date of the decision	Name of the medicinal product	INN (International Non-Proprietary Name)	Holder of the marketing authorisation	Number of the entry in the Community Register	Pharmaceutical form	ATC code (Anatomical Therapeutic Chemical Code)	Date of notification
10.11.2022	VidPrevtyn Beta	COVID-19 vaccine (recombinant, adjuvanted)	Sanofi Pasteur 14 Espace Henry Vallée, 69007 Lyon, France	EU/1/21/1580	Solution and emulsion for emulsion for injection	J07BX03	10.11.2022

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
NETHERLANDS

---

[1] OJ L 136, 30.4.2004, p. 1.
[2] OJ L 4, 7.1.2019, p. 43.

ISSN 1977-091X (electronic edition)
ISSN 1725-2423 (paper edition)

Publications Office
of the European Union
L-2985 Luxembourg
LUXEMBOURG

EN